They don’t agree on the details, but both Republicans and Democrats in the Senate are ready to ramp up oversight of a federal drug discount program that hospitals generally support — and drug makers tend to want to rein in.
On its face, the increasing congressional scrutiny seems like a win for the pharmaceutical industry, which has bucked against the status quo. But lawmakers at a Tuesday hearing on the program, known as 340B, signaled an interest in taking aim at both industries.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
